Applying Trial Data to Real-World Practice in ALK+ NSCLC

EP: 1.The Evolution of ALK+ NSCLC Care

EP: 2.Lorlatinib in Focus: Survival, Brain Metastases, and Beyond

EP: 3.Choosing Wisely: Insights from an MAIC and eXalt3

Now Viewing

EP: 4.Applying Trial Data to Real-World Practice in ALK+ NSCLC

EP: 5.Key Differences Among ALK Inhibitors

EP: 6.Navigating ALK Inhibitor Toxicities

EP: 7.Lorlatinib’s Unique Challenges: Managing Cognitive and Metabolic AEs

EP: 8.Long-Term Success: Educating and Supporting Patients on ALK Inhibitors

EP: 9.Equitable Access to Molecular Testing and Treatment Prioritization

EP: 10.Next Steps: Post-Frontline Therapies and Resistance in ALK+ NSCLC

EP: 11.Education and Support After Progression ALK Inhibitors

EP: 12.Looking Ahead: The Next Frontier in ALK+ NSCLC Therapy

Real-World Settings and Evolution of Frontline Therapy

Key Themes:

• Comparison of clinical trial outcomes to real-world patient experiences
• Impact of clinical data (ALINA, CROWN, eXalt3) on frontline therapy choices
• Evolving perspective on frontline therapies for ALK+ NSCLC

Notable Insights:

• Grizzard addressed how well outcomes from trials like CROWN and eXalt3 reflect real-world patient experiences

Dr Dietrich summarized how recent clinical data has changed the landscape of frontline therapies for ALK+ NSCLC